10
Participants
Start Date
February 23, 2022
Primary Completion Date
June 1, 2024
Study Completion Date
June 1, 2024
Brexanolone
Brexanolone injection is an Federal Drug Administration (FDA)-approved drug to treat postpartum depression. It is administered via continuous intravenous infusion over a 60-hour time period.
UNC Hospitals, Chapel Hill
Collaborators (1)
Sage Therapeutics
INDUSTRY
University of North Carolina, Chapel Hill
OTHER